Enabling Early Disease Detection and Treatment Next Gen Patented - PowerPoint PPT Presentation

Enabling Early Disease Detection and Treatment Next Gen Patented Detection Chemistry • Replaces chemicals in ‘Gold Standard’ $34B ELISA market • Up to 30x sensitivity increase with standard instrumentation • Accelerates drug discovery and development • Enables early disease detection

Enabling Early Disease Detection and Treatment Customers & Partners: • PharmBio Ecosystem • Next Gen Diagnostics Key partnerships underway Seeking additional partners and expansion capital

Immunomic Therapeutics (ITI): value proposition, market, competitive advantages and management VALUE PROPOSITION : ITI’s LAMP-vax™ Technology is the “missing link” that enhances the effectiveness of DNA vaccines. It has the ability to make DNA vaccines work, which will reign in an era of simple, inexpensive and effective vaccinations for a wide spectrum of diseases. DNA and other nucleic acid vaccines have been in development since the 1990s, and with technologies such as ours that will make them a reality, this class of vaccines is poised to revolutionize the vaccine industry and public health as a whole. MARKETS: GLOBAL VACCINES, ALLERGY & ANIMAL HEALTH: The global human vaccine market is rapidly growing: Global market >$25 billion in 2011 with >30% AGR, Dominated by “Big 5” Pharma companies. The Allergy market is >$1.0B in 2010 for immunotherapeutics - Allergy Market is >$11B for symptom therapy. The Animal health vaccine sales were $4.0B in 2010, Fragmented market: companion & feedstock animals, Growth driven by entry into new markets like cancer & allergy. COMPETITIVE ADVANTAGES: DNA Vaccines as a class present great versatility, safety and simplicity. LAMP-vax DNA technology improves immunogenicity of DNA vacicnes through a low cost, scalable solution that eliminates the need for expensive and painful delivery systems such as electroporation and the danger and unknowns of molecular adjuvants such as cytokines. In particular, our technology’s advantages include: MHC-II Targeting Strategy Necessary for Clinical Relevancy, For Lysosomal Targeting, a Stablization Domain is Required, Proven Safety in the Clinic, Multiplexing Antigens, Plug & Play Vaccine Design for Rapid Product Line Development. MANAGEMENT: ITI’s Management Team includes experienced and respected biotechnology professionals providing strong scientific analysis supporting business management's efforts in innovative technology collaborations and creative business development. With collectively well over 100 years of industry relevant experience, ITI's Management Team is creating a world-class biotechnology company Page  3

DiskCorp in an Nutshell Problem – Approx. 90 million HDDs are being destroyed annually due to the lack of a portable HDD repair solution Value Proposition – DiskCorp’s industry leading repair technology delivers a solution for these destroyed HDDs – Substantially improves P&L by providing repair at 33% of the value of a new HDD Solution – Software based HDD Test & Repair; industry’s best yield 40% to 60%+ of failed HDD’s repaired Executives – DiskCorp’s management team’s 80-year history of providing Innovative data storage and aftermarket solutions – Mr. Ross Johnston CEO served as VP Engineering at Seagate Technology and served as CEO of a subsidiary of Hyundai – Mr. Dennis Cain COO served as VP of service for HP and is considered one of the leading experts in information technology service Market – $23 Billion Market – Market Growth 14% per year – 50% not served due to security requirements 4

The Company – Founded in 2010 focused on repair and recovery of HDD’s – Headquartered in San José, California – Revenue for fiscal year 2014 will be $1.6 Million The Product – DiskCorp technology opens the non-addressable portion of the market Customers – Symantec, Techway Services, Walmart – Round2 / Avnet, CTDI, Riverbed – Arrow Electronics Competition Repair Erasure TeriSci Industries Blanco Tabernus Ji2 5

DocView’s disease-flexible e-health platform allows for the rapid development/deployment of patient-integrated health solutions designed to monitor and prevent negative clinical outcomes, thereby saving health care dollars • Real-time patient-centric solutions help connect relevant health care providers across multiple platforms and health care systems • When warranted, pre-defined expert clinical criteria regulate the types and level of interventions needed. • DocView’s e-health platform is highly scalable and can be easily applied across multiple health care disciplines to help connect patient providers and improve clinical outcomes. • New features have been specifically engineered and tested to meet MU reporting requirements and ACO quality & care required measures.

The Market • An estimated 35 million hospital readmissions and 120 million emergency room visits occur each year • Medicare readmissions are estimated to cost the health care system $12 billion/year • Technology can be used to prevent readmissions and monitor patients in acute settings DocView’s e-health platform software • Patient-centric, disease targeted, expert criteria/algorithm driven digital health solutions to address and prevent negative clinical outcomes . Management • Jack Miladin, CEO – experienced life-science entrepreneur who started and grew several companies in home medical equipment, home infusion, homecare respiratory and renal dialysis. • Most recently was Co-Founder and President of Sleepcare Centers, Inc, one of the country’s largest providers of sleep diagnostics and treatment equipment